The big cost of big medicine – calculating the rent in private healthcare

  title={The big cost of big medicine – calculating the rent in private healthcare},
  author={Mark Stelzner and Daniel Taekmin Nam},
  journal={Review of Social Economy},
  • Mark Stelzner, D. Nam
  • Published 11 August 2020
  • Medicine, Political Science
  • Review of Social Economy
As a country, the United States spends significantly more on healthcare than other advanced industrialized countries, and Americans have comparably worse health outcomes. Both are developments of t... 



The Industrial Organization of Health Care Markets

This paper analyzes the industrial organization literature on health care markets focusing on the impact of competition on price, quality and treatment decisions for health care providers and health insurers and concludes with a discussion of research opportunities for industrial organization economists.

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

It is argued that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines.

The Effects of Competition on Variation in the Quality and Cost of Medical Care

It is found that low-valuation patients in less-competitive markets receive more intensive treatment than in more- competitive markets, but have statistically similar health outcomes, while high-valuations patients inLess- Competitive Markets receive less intensive treatment, and have significantly worse health outcomes.

'Examining the Impact of Health Care Consolidation' Statement before the Committee on Energy and Commerce, Oversight and Investigations Subcommittee, U.S. House of Representatives

Evidence shows that consolidation between close competitors leads to substantial price increases for hospitals, insurers, and physicians, without offsetting gains in improved quality or enhanced efficiency, which is causing serious harm to patients and to the health care system as a whole.

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

The most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights, enhancing competition by ensuring timely generic drug availability, and more effectively educating patients, prescribers, payers, and policy makers about these choices.

Consolidation and the transformation of competition in health insurance.

This paper presents data on fifty state and substate insurance markets, in terms of the 2003 relative shares of the largest health plans and the antitrust index of concentration, to assess private insurers' prospects in an increasingly consolidated industry.

Evaluating the Impact of Health Insurance Industry Consolidation: Learning from Experience.

Data on enrollment, premiums, and costs of commercial health insurance--by insurer, plan, customer segment, and local market--would help understand whether, when, and for whom consolidation is harmful or beneficial.

Costs of health care administration in the United States and Canada.

The gap between U.S. and Canadian spending on health care administration has grown to 752 dollars per capita, and a large sum might be saved in the United States if administrative costs could be trimmed by implementing a Canadian-style health care system.

Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?

This work discusses the current EU price regulation schemes for drugs from a third-party payer’s perspective, using the well known management tool of Porter's competitive business strategies to discuss policy implications and future scenarios from a European integrated perspective.